ABSORB II Randomized Controlled Trial

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Abbott Vascular
ClinicalTrials.gov Identifier:
NCT01425281
First received: August 25, 2011
Last updated: April 23, 2014
Last verified: April 2014
  Purpose

Prospective, randomized (2:1), active control, single blinded, parallel two-arm, multi-center clinical investigation using Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System (ABSORB BVS); compared to Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System (XIENCE)


Condition Intervention
Coronary Artery Disease
Device: Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
Device: Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: ABSORB II RANDOMIZED CONTROLLED TRIAL A Clinical Evaluation to Compare the Safety, Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System Against XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Subjects With Ischemic Heart Disease Caused by de Novo Native Coronary Artery Lesions

Resource links provided by NLM:


Further study details as provided by Abbott Vascular:

Primary Outcome Measures:
  • Vasomotion assessed by change in Mean Lumen Diameter (MLD) between pre- and post-nitrate QCA (quantitative coronary angiography) (superiority) [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Minimum Lumen Diameter (MLD) post nitrate minus MLD post procedure post nitrate by QCA (quantitative coronary angiography) (non-inferiority, reflex to superiority) [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Device success [ Time Frame: From the start of index procedure to end of index procedure ] [ Designated as safety issue: No ]
    Successful delivery and deployment of the first study scaffold/stent the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 50% by QCA.

  • Procedural success [ Time Frame: From the start of index procedure to end of index procedure ] [ Designated as safety issue: No ]
    Achievement of final in-scaffold/stent residual stenosis of less than 50% by QCA with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay.

  • Death (Cardiac, Vascular, Non-Cardiovascular) [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
    Death per ARC definition

  • Death (Cardiac, Vascular, Non-Cardiovascular) [ Time Frame: 180 Days ] [ Designated as safety issue: Yes ]
    Per ARC Definition

  • Death (Cardiac, Vascular, Non-Cardiovascular) [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    Death per ARC definition

  • Death (Cardiac, Vascular, Non-Cardiovascular) [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    Per ARC definition

  • Myocardial Infarction (MI: QMI and NQMI)* [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
    * will be adjudicated according Historical Extended Definition (modified ARC Definitions),Per Protocol Definition of MI also known as the World Health Organization Definition of MI, and third MI definition

  • Myocardial Infarction (MI: QMI and NQMI)* [ Time Frame: 180 days ] [ Designated as safety issue: Yes ]
    * will be adjudicated according Historical Extended Definition (modified ARC Definitions),Per Protocol Definition of MI also known as the World Health Organization Definition of MI, and third MI definition

  • Myocardial Infarction (MI: QMI and NQMI)* [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    * will be adjudicated according Historical Extended Definition (modified ARC Definitions),Per Protocol Definition of MI also known as the World Health Organization Definition of MI, and third MI definition

  • Myocardial Infarction (MI: QMI and NQMI)* [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    * will be adjudicated according Historical Extended Definition (modified ARC Definitions),Per Protocol Definition of MI also known as the World Health Organization Definition of MI, and third MI definition

  • Target Lesion Revascularization (TLR) [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Target Lesion Revascularization (TLR) [ Time Frame: 180 days ] [ Designated as safety issue: Yes ]
  • Target Lesion Revascularization (TLR) [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Target Lesion Revascularization (TLR) [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Target Vessel Revascularization (TVR) [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Target Vessel Revascularization (TVR) [ Time Frame: 180 days ] [ Designated as safety issue: Yes ]
  • Target Vessel Revascularization (TVR) [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Target Vessel Revascularization (TVR) [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Non-Target Vessel Revascularization (NTVR) [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Non-Target Vessel Revascularization (NTVR) [ Time Frame: 180 days ] [ Designated as safety issue: Yes ]
  • Non-Target Vessel Revascularization (NTVR) [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Non-Target Vessel Revascularization (NTVR) [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • All coronary revascularization [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • All coronary revascularization [ Time Frame: 180 days ] [ Designated as safety issue: Yes ]
  • All coronary revascularization [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • All coronary revascularization [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Death/All MI [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Death/All MI [ Time Frame: 180 days ] [ Designated as safety issue: Yes ]
  • Death/All MI [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Death/All MI [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Cardiac Death/TV-MI/CI-TLR [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Cardiac Death/TV-MI/CI-TLR [ Time Frame: 180 days ] [ Designated as safety issue: Yes ]
  • Cardiac Death/TV-MI/CI-TLR [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Cardiac Death/TV-MI/CI-TLR [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Cardiac Death/All MI/CI-TLR (Major Adverse Cardiac Events (MACE)) [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Cardiac Death/All MI/CI-TLR (Major Adverse Cardiac Events (MACE)) [ Time Frame: 180 days ] [ Designated as safety issue: Yes ]
  • Cardiac Death/All MI/CI-TLR (Major Adverse Cardiac Events (MACE)) [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Cardiac Death/All MI/CI-TLR (Major Adverse Cardiac Events (MACE)) [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Cardiac Death/All MI/CI-TVR (Target Vessel Failure (TVF)) [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Cardiac Death/All MI/CI-TVR (Target Vessel Failure (TVF)) [ Time Frame: 180 days ] [ Designated as safety issue: Yes ]
  • Cardiac Death/All MI/CI-TVR (Target Vessel Failure (TVF)) [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Cardiac Death/All MI/CI-TVR (Target Vessel Failure (TVF)) [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Death/All MI/All revascularization (DMR) [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Death/All MI/All revascularization (DMR) [ Time Frame: 180 days ] [ Designated as safety issue: Yes ]
  • Death/All MI/All revascularization (DMR) (Subject-oriented endpoint) [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    Composite Endpoint

  • Death/All MI/All revascularization (DMR) [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Scaffold/Stent Thrombosis [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Scaffold/Stent Thrombosis [ Time Frame: 180 days ] [ Designated as safety issue: Yes ]
  • Scaffold/Stent Thrombosis [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    Timing (acute, sub-acute, late and very late) Evidence (Definite, Probable and Possible)

  • Scaffold/Stent Thrombosis [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    Timing (acute, sub-acute, late and very late) Evidence (Definite, Probable and Possible)

  • Death (Cardiac, Vascular, Non-Cardiovascular) [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
    Per ARC definition

  • Death (Cardiac, Vascular, Non-Cardiovascular) [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
    Per ARC definition

  • Death (Cardiac, Vascular, Non-Cardiovascular) [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
    Per ARC definition

  • Myocardial Infarction (MI: QMI and NQMI)* [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
    * will be adjudicated according Historical Extended Definition (modified ARC Definitions),Per Protocol Definition of MI also known as the World Health Organization Definition of MI, and third MI definition

  • Myocardial Infarction (MI: QMI and NQMI)* [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
    * will be adjudicated according Historical Extended Definition (modified ARC Definitions),Per Protocol Definition of MI also known as the World Health Organization Definition of MI, and third MI definition

  • Myocardial Infarction (MI: QMI and NQMI)* [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
    * will be adjudicated according Historical Extended Definition (modified ARC Definitions),Per Protocol Definition of MI also known as the World Health Organization Definition of MI, and third MI definition

  • Target Lesion Revascularization (TLR) [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • Target Lesion Revascularization (TLR) [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
  • Target Lesion Revascularization (TLR) [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • Target Vessel Revascularization (TVR) [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • Target Vessel Revascularization (TVR) [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
  • Target Vessel Revascularization (TVR) [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • Non-Target Vessel Revascularization (NTVR) [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • Non-Target Vessel Revascularization (NTVR) [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
  • All coronary revascularization [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • All coronary revascularization [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
  • All coronary revascularization [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • Death/All MI [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • Death/All MI [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
  • Death/All MI [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • Cardiac Death/TV-MI/CI-TLR [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • Cardiac Death/TV-MI/CI-TLR [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
  • Cardiac Death/TV-MI/CI-TLR [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • Cardiac Death/All MI/CI-TLR (Major Adverse Cardiac Events (MACE)) [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • Cardiac Death/All MI/CI-TLR (Major Adverse Cardiac Events (MACE)) [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
  • Cardiac Death/All MI/CI-TLR (Major Adverse Cardiac Events (MACE)) [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • Cardiac Death/All MI/CI-TVR (Target Vessel Failure (TVF)) [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • Cardiac Death/All MI/CI-TVR (Target Vessel Failure (TVF)) [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
  • Cardiac Death/All MI/CI-TVR (Target Vessel Failure (TVF)) [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • Death/All MI/All revascularization (DMR) [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • Death/All MI/All revascularization (DMR) [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
  • Death/All MI/All revascularization (DMR) [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • Scaffold/Stent Thrombosis [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
    Timing (acute, sub-acute, late and very late) Evidence (Definite, Probable and Possible)

  • Scaffold/Stent Thrombosis [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
    Timing (acute, sub-acute, late and very late) Evidence (Definite, Probable and Possible)

  • Scaffold/Stent Thrombosis [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
    Timing (acute, sub-acute, late and very late) Evidence (Definite, Probable and Possible)

  • Non-Target Vessel Revascularization (NTVR) [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 501
Study Start Date: November 2011
Estimated Study Completion Date: July 2018
Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: XIENCE™
Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
Device: Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
XIENCE implantation in the treatment of coronary artery disease.
Experimental: ABSORB BVS™
Experimental: Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
Device: Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
ABSORB BVS implantation in the treatment of coronary artery disease.

Detailed Description:

In the USA, ABSORB BVS is currently in development at Abbott Vascular. Not available for sale in the US.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

General Inclusion Criteria

  • Subject must be at least 18 years of age and less than 85 years of age.
  • Subject must agree not to participate in any other clinical investigation for a period of three years following the index procedure. This includes clinical trials of medication and invasive procedures. Questionnaire-based studies, or other studies that are non-invasive and do not require medication are allowed.
  • Subject is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the ABSORB BVS system and he/she or his/her legally authorized representative provides written informed consent prior to any Clinical Investigation related procedure, as approved by the appropriate Ethics Committee.
  • Subject must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia).
  • Subject must be an acceptable candidate for coronary artery bypass graft (CABG) surgery
  • Subject must agree to undergo all clinical investigation plan-required follow-up visits, exercise testing, blood draw as well as adherence to ESC Guidelines and completion of quality of life questionnaires and of a subject diary to collect information including but not limited to tobacco usage, food intake, daily exercise and body weight

Angiographic Inclusion Criteria

  • One or two de novo native lesions each located in a different epicardial vessel.
  • If two treatable lesions meet the eligibility criteria, they must be in separate major epicardial vessels (LAD with septal and diagonal branches, LCX with obtuse marginal and/or ramus intermedius branches and RCA and any of its branches).
  • Lesion(s) must have a visually estimated diameter stenosis of ≥50% and <100% with a TIMI flow of ≥1.
  • Lesion(s) must be located in a native coronary artery with Dmax by on-line QCA of ≥2.25 mm and ≤3.8 mm.
  • Lesion(s) must be located in a native coronary artery with lesion(s) length by on-line QCA of ≤48 mm.
  • Percutaneous interventions for lesions in a non-target vessel are allowed if done ≥30 days prior to or if planned to be done 2 years after the index procedure.
  • Percutaneous intervention for lesions in the target vessel are allowed if done >6 months prior to or if planned to be done 2 years after the index procedure.

Exclusion Criteria:

  • Known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, antiplatelet medication specified for use in the study (clopidogrel and prasugrel and ticlopidine, inclusive), everolimus, poly (L-lactide), poly (DL-lactide), cobalt, chromium, nickel, tungsten, acrylic and fluoro polymers or contrast sensitivity that cannot be adequately pre-medicated.
  • Subject has a known diagnosis of acute myocardial infarction (AMI) at any time preceding the index procedure and relevant cardiac enzymes (according to local standard hospital practice) have not returned within normal limits at the time of procedure.
  • Evidence of ongoing acute myocardial infarction in ECG prior to procedure
  • Subject has current unstable arrhythmias.
  • Left ventricular ejection fraction (LVEF) < 30%.
  • Subject has received a heart transplant or any other organ transplant or is on a waiting list for any organ transplant.
  • Subject is receiving or scheduled to receive chemotherapy for malignancy within 30 days prior to or after the procedure.
  • Subject is receiving immunosuppressant therapy and/or has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus, rheumatoid arthritis, severe asthma requiring immunosuppressive medication, etc.).
  • Subject is receiving chronic anticoagulation therapy that can not be stopped and restarted according to local hospital standard procedures.
  • Elective surgery is planned within 2 years after the procedure that will require discontinuing either aspirin, clopidogrel, prasugrel or ticlopidine.
  • Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3, a WBC of <3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis)
  • Known renal insufficiency (e.g., eGFR <60 ml/kg/1.73m² or serum creatinine level of >2.5 mg/dL, or subject on dialysis).
  • History of bleeding diathesis or coagulopathy or will refuse blood transfusions.
  • Subject has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) within the past 6 months.
  • Pregnant or nursing subjects and those who plan pregnancy in the period up to 3 years following index procedure. (Female subjects of child-bearing potential must have a negative pregnancy test done within 28 days prior to the index procedure and contraception must be used during participation in this trial)
  • Other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) as per physician judgment that may cause non-compliance with the protocol or confound the data interpretation or is associated with a limited life expectancy.
  • Subject is already participating in another clinical investigation that has not yet reached its primary endpoint.
  • Subject is belonging to a vulnerable population (per investigator's judgment, e.g., subordinate hospital staff or sponsor staff) or subject unable to read or write.

Angiographic Exclusion Criteria

  • Target lesion which prevents adequate (residual stenosis at target lesion(s) is ≤ 40% by visual assessment) coronary pre-dilatation.
  • Target lesion in left main trunk.
  • Aorto-ostial target lesion (within 3 mm of the aorta junction).
  • Target lesion located within 2 mm of the origin of the LAD or LCX.
  • Target lesion located distal to a diseased (vessel irregularity per angiogram and >20% stenosed lesion) arterial or saphenous vein graft.
  • Target lesion involving a bifurcation lesion with side branch ≥2 mm in diameter, or with a side branch <2mm in diameter requiring guide wire protection or dilatation.
  • Total occlusion (TIMI flow 0), prior to wire crossing
  • Excessive tortuosity (≥ two 45° angles), or extreme angulation (≥90 °) proximal to or within the target lesion.
  • Restenotic from previous intervention
  • Heavy calcification proximal to or within the target lesion.
  • Target lesion involves myocardial bridge.
  • Target vessel contains thrombus as indicated in the angiographic images.
  • Additionally clinically significant lesion(s) (≥ 40% diameter stenosis by visual assessment) for which PCI may be required <2 years after the index procedure.
  • Subject has received brachytherapy in any epicardial vessel (including side branches)
  • Subject has a high probability that a procedure other than pre-dilatation and study device implantation and (if necessary) post-dilatation will be required at the time of index procedure for treatment of the target vessel (e.g. atherectomy, cutting balloon)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01425281

Locations
Belgium
Abbott Vascular International BVBA
Brussels, Belgium, 0886.537.933
Sponsors and Collaborators
Abbott Vascular
Investigators
Principal Investigator: Patrick W. Serruys, MD, PhD Erasmus Medical Center
Principal Investigator: Bernard Chevalier, MD Institut Jacques Cartier (ICPS)
  More Information

No publications provided by Abbott Vascular

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Abbott Vascular
ClinicalTrials.gov Identifier: NCT01425281     History of Changes
Other Study ID Numbers: 10-393, CIV-11-10-002627
Study First Received: August 25, 2011
Last Updated: April 23, 2014
Health Authority: Austria: Federal Office for Safety in Health Care
Belgium: Federal Agency for Medicinal Products and Health Products
Denmark: Danish Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Italy: National Monitoring Centre for Clinical Trials - Ministry of Health
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
New Zealand: Institutional Review Board
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Portugal: National Pharmacy and Medicines Institute
Spain: Ministry of Health
Switzerland: Swissmedic
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration

Keywords provided by Abbott Vascular:
Bioabsorbable
Coronary scaffold
Coronary Stent
Everolimus
Drug eluting stents
Angioplasty
Coronary artery disease
Total coronary occlusion
Coronary artery restenosis
Stent thrombosis
Myocardial ischemia
Coronary artery stenosis

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Everolimus
Sirolimus
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents

ClinicalTrials.gov processed this record on September 16, 2014